Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2
• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity.
Gespeichert in:
| Autor*in: |
Malipiero, Giacomo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Li-CO - Zhang, Peng-Fang ELSEVIER, 2022, international journal of clinical chemistry and applied molecular biology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:524 ; year:2022 ; day:1 ; month:01 ; pages:11-17 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.cca.2021.11.023 |
|---|
| Katalog-ID: |
ELV056254210 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV056254210 | ||
| 003 | DE-627 | ||
| 005 | 20230624230710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cca.2021.11.023 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica |
| 035 | |a (DE-627)ELV056254210 | ||
| 035 | |a (ELSEVIER)S0009-8981(21)00413-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 660 |q VZ |
| 082 | 0 | 4 | |a 660 |q VZ |
| 084 | |a 58.10 |2 bkl | ||
| 100 | 1 | |a Malipiero, Giacomo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
| 264 | 1 | |c 2022 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. | ||
| 650 | 7 | |a COVID-19 |2 Elsevier | |
| 650 | 7 | |a SARS-CoV-2 |2 Elsevier | |
| 650 | 7 | |a BNT162b2 |2 Elsevier | |
| 650 | 7 | |a Immunogenicity |2 Elsevier | |
| 650 | 7 | |a Anti-S-RBD |2 Elsevier | |
| 650 | 7 | |a Neutralizing antibody |2 Elsevier | |
| 700 | 1 | |a D'Agaro, Pierlanfranco |4 oth | |
| 700 | 1 | |a Segat, Ludovica |4 oth | |
| 700 | 1 | |a Moratto, Anna |4 oth | |
| 700 | 1 | |a Villalta, Danilo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Zhang, Peng-Fang ELSEVIER |t Li-CO |d 2022 |d international journal of clinical chemistry and applied molecular biology |g Amsterdam [u.a.] |w (DE-627)ELV008356149 |
| 773 | 1 | 8 | |g volume:524 |g year:2022 |g day:1 |g month:01 |g pages:11-17 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cca.2021.11.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 58.10 |j Verfahrenstechnik: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 524 |j 2022 |b 1 |c 0101 |h 11-17 |g 7 | ||
| author_variant |
g m gm |
|---|---|
| matchkey_str |
malipierogiacomodagaropierlanfrancosegat:2022----:ogemeaoatrdgttratrn122acntointirrdyosfetai |
| hierarchy_sort_str |
2022 |
| bklnumber |
58.10 |
| publishDate |
2022 |
| allfields |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
| spelling |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
| allfields_unstemmed |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
| allfieldsGer |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
| allfieldsSound |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
| language |
English |
| source |
Enthalten in Li-CO Amsterdam [u.a.] volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 |
| sourceStr |
Enthalten in Li-CO Amsterdam [u.a.] volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Verfahrenstechnik: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
COVID-19 SARS-CoV-2 BNT162b2 Immunogenicity Anti-S-RBD Neutralizing antibody |
| dewey-raw |
660 |
| isfreeaccess_bool |
false |
| container_title |
Li-CO |
| authorswithroles_txt_mv |
Malipiero, Giacomo @@aut@@ D'Agaro, Pierlanfranco @@oth@@ Segat, Ludovica @@oth@@ Moratto, Anna @@oth@@ Villalta, Danilo @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV008356149 |
| dewey-sort |
3660 |
| id |
ELV056254210 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056254210</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624230710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cca.2021.11.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056254210</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0009-8981(21)00413-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Malipiero, Giacomo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COVID-19</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BNT162b2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunogenicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-S-RBD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neutralizing antibody</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">D'Agaro, Pierlanfranco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Segat, Ludovica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moratto, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Villalta, Danilo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Zhang, Peng-Fang ELSEVIER</subfield><subfield code="t">Li-CO</subfield><subfield code="d">2022</subfield><subfield code="d">international journal of clinical chemistry and applied molecular biology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV008356149</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:524</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:11-17</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cca.2021.11.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.10</subfield><subfield code="j">Verfahrenstechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">524</subfield><subfield code="j">2022</subfield><subfield code="b">1</subfield><subfield code="c">0101</subfield><subfield code="h">11-17</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| author |
Malipiero, Giacomo |
| spellingShingle |
Malipiero, Giacomo ddc 660 bkl 58.10 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
| authorStr |
Malipiero, Giacomo |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008356149 |
| format |
electronic Article |
| dewey-ones |
660 - Chemical engineering |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
660 VZ 58.10 bkl Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier |
| topic |
ddc 660 bkl 58.10 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody |
| topic_unstemmed |
ddc 660 bkl 58.10 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody |
| topic_browse |
ddc 660 bkl 58.10 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p d pd l s ls a m am d v dv |
| hierarchy_parent_title |
Li-CO |
| hierarchy_parent_id |
ELV008356149 |
| dewey-tens |
660 - Chemical engineering |
| hierarchy_top_title |
Li-CO |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008356149 |
| title |
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
| ctrlnum |
(DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 |
| title_full |
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
| author_sort |
Malipiero, Giacomo |
| journal |
Li-CO |
| journalStr |
Li-CO |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
11 |
| author_browse |
Malipiero, Giacomo |
| container_volume |
524 |
| physical |
7 |
| class |
660 VZ 58.10 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Malipiero, Giacomo |
| doi_str_mv |
10.1016/j.cca.2021.11.023 |
| dewey-full |
660 |
| title_sort |
long-term decay of anti-rbd igg titers after bnt162b2 vaccination is not mirrored by loss of neutralizing bioactivity against sars-cov-2 |
| title_auth |
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
| abstract |
• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. |
| abstractGer |
• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. |
| abstract_unstemmed |
• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
| url |
https://doi.org/10.1016/j.cca.2021.11.023 |
| remote_bool |
true |
| author2 |
D'Agaro, Pierlanfranco Segat, Ludovica Moratto, Anna Villalta, Danilo |
| author2Str |
D'Agaro, Pierlanfranco Segat, Ludovica Moratto, Anna Villalta, Danilo |
| ppnlink |
ELV008356149 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.cca.2021.11.023 |
| up_date |
2024-07-06T19:52:10.260Z |
| _version_ |
1803860605937909760 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056254210</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624230710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cca.2021.11.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056254210</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0009-8981(21)00413-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Malipiero, Giacomo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COVID-19</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BNT162b2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunogenicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-S-RBD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neutralizing antibody</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">D'Agaro, Pierlanfranco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Segat, Ludovica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moratto, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Villalta, Danilo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Zhang, Peng-Fang ELSEVIER</subfield><subfield code="t">Li-CO</subfield><subfield code="d">2022</subfield><subfield code="d">international journal of clinical chemistry and applied molecular biology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV008356149</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:524</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:11-17</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cca.2021.11.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.10</subfield><subfield code="j">Verfahrenstechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">524</subfield><subfield code="j">2022</subfield><subfield code="b">1</subfield><subfield code="c">0101</subfield><subfield code="h">11-17</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.4000454 |